Skip to main content
Erschienen in: Journal of Assisted Reproduction and Genetics 3/2019

27.11.2018 | Genetics

Rare genetic variants potentially involved in ovarian hyperstimulation syndrome

verfasst von: Katrien Stouffs, Sari Daelemans, Samuel Santos-Ribeiro, Sara Seneca, Alexander Gheldof, Ali Sami Gürbüz, Michel De Vos, Herman Tournaye, Christophe Blockeel

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aim to investigate whether there is a genetic predisposition in women who developed ovarian hyperstimulation syndrome (OHSS) after GnRH antagonist protocol with GnRH agonist trigger and freeze-all approach.

Methods

Four patients with OHSS after GnRH agonist trigger and freeze-all approach were gathered from the worldwide patient population. These patients were analyzed through Whole Exome Sequencing. In this study known causes of OHSS were investigated and new causes present in at least two individuals were searched for.

Results

In the first part of the study, we evaluated the presence of mutations in genes already known to be involved in OHSS. In PGR and TP53, heterozygous alterations were detected. PGR is predicted to be involved in progesterone resistance with a recessive inheritance pattern and is, therefore, not considered as being causal. The consequences of the variant detected in TP53 currently remain unknown. In part 2 of the study, we assessed the clinical significance of variants in genes previously not linked to OHSS. We especially focused on genes with variants present in ≥ 2 patients. Two patients have variants in the FLT4 gene. Mutations in this gene are linked to hereditary lymphedema, but no link to OHSS has been described.

Conclusions

Defining a genetic predisposition for OHSS is essential in view of prevention. In this study, a potential link between the FLT4 gene and OHSS has been suggested. Future functional studies are essential to define a more precise involvement of the detected variants in the development of OHSS.
Literatur
1.
Zurück zum Zitat Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update. 2003;9:77–96.CrossRefPubMed Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update. 2003;9:77–96.CrossRefPubMed
2.
Zurück zum Zitat Soares SR, Amols MH, Hudson SBA, et al. Etiology of OHSS and use of dopamine agonists. Fertil Steril. 2012;97:517–22.CrossRefPubMed Soares SR, Amols MH, Hudson SBA, et al. Etiology of OHSS and use of dopamine agonists. Fertil Steril. 2012;97:517–22.CrossRefPubMed
3.
Zurück zum Zitat Fatemi HM, Garcia-Velasco J. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. Fertil Steril. 2015;103:870–3.CrossRefPubMed Fatemi HM, Garcia-Velasco J. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. Fertil Steril. 2015;103:870–3.CrossRefPubMed
4.
Zurück zum Zitat Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update. 1997;3:255–66.CrossRefPubMed Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update. 1997;3:255–66.CrossRefPubMed
5.
Zurück zum Zitat Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 1995;80:1967–71.PubMed Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 1995;80:1967–71.PubMed
6.
Zurück zum Zitat Walter JW, North PE, Waner M, Mizeracki A, Blei F, Walker JWT, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer. 2002;33:295–303.CrossRefPubMed Walter JW, North PE, Waner M, Mizeracki A, Blei F, Walker JWT, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer. 2002;33:295–303.CrossRefPubMed
9.
Zurück zum Zitat Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study. Fertil Steril. 2011;95:2029–33.CrossRefPubMed Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study. Fertil Steril. 2011;95:2029–33.CrossRefPubMed
10.
Zurück zum Zitat Fatemi HM, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril. 2014;101:1008–11.CrossRefPubMed Fatemi HM, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril. 2014;101:1008–11.CrossRefPubMed
11.
Zurück zum Zitat Gurbuz AS, Gode F, Ozcimen N, Isik AZ. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod BioMed Online. 2014;29:541–4.CrossRefPubMed Gurbuz AS, Gode F, Ozcimen N, Isik AZ. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod BioMed Online. 2014;29:541–4.CrossRefPubMed
12.
Zurück zum Zitat Ling S-Y, Chong K-M, Hwang J-L. Persistent megalocystic ovary following in vitro fertilization in a postpartum patient with polycystic ovarian syndrome. Taiwan J Obstet Gynecol. 2006;45:70–2.CrossRefPubMed Ling S-Y, Chong K-M, Hwang J-L. Persistent megalocystic ovary following in vitro fertilization in a postpartum patient with polycystic ovarian syndrome. Taiwan J Obstet Gynecol. 2006;45:70–2.CrossRefPubMed
13.
Zurück zum Zitat Santos-Ribeiro S, Polyzos NP, Stouffs K, de Vos M, Seneca S, Tournaye H, et al. Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition. J Assist Reprod Genet. 2015;32:1063–8.CrossRefPubMedPubMedCentral Santos-Ribeiro S, Polyzos NP, Stouffs K, de Vos M, Seneca S, Tournaye H, et al. Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition. J Assist Reprod Genet. 2015;32:1063–8.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Montanelli L, Delbaere A, Di Carlo C, et al. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2004;89:1255–8.CrossRefPubMed Montanelli L, Delbaere A, Di Carlo C, et al. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2004;89:1255–8.CrossRefPubMed
15.
Zurück zum Zitat Altmäe S, Hovatta O, Stavreus-Evers A, Salumets A. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Hum Reprod Update. 2011;17:813–28.CrossRefPubMed Altmäe S, Hovatta O, Stavreus-Evers A, Salumets A. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Hum Reprod Update. 2011;17:813–28.CrossRefPubMed
16.
Zurück zum Zitat Lledo B, Ortiz JA, Llacer J, Bernabeu R. Pharmacogenetics of ovarian response. Pharmacogenomics. 2014;15:885–93.CrossRefPubMed Lledo B, Ortiz JA, Llacer J, Bernabeu R. Pharmacogenetics of ovarian response. Pharmacogenomics. 2014;15:885–93.CrossRefPubMed
17.
Zurück zum Zitat Boudjenah R, Molina-Gomes D, Torre A, Boitrelle F, Taieb S, Dos Santos E, et al. Associations between individual and combined polymorphisms of the TNF and VEGF genes and the embryo implantation rate in patients undergoing in vitro fertilization (IVF) programs. PLoS One. 2014;9:e108287.CrossRefPubMedPubMedCentral Boudjenah R, Molina-Gomes D, Torre A, Boitrelle F, Taieb S, Dos Santos E, et al. Associations between individual and combined polymorphisms of the TNF and VEGF genes and the embryo implantation rate in patients undergoing in vitro fertilization (IVF) programs. PLoS One. 2014;9:e108287.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Boudjenah R, Molina-Gomes D, Torre A, Bergere M, Bailly M, Boitrelle F, et al. Genetic polymorphisms influence the ovarian response to rFSH stimulation in patients undergoing in vitro fertilization programs with ICSI. PLoS One. 2012;7:e38700.CrossRefPubMedPubMedCentral Boudjenah R, Molina-Gomes D, Torre A, Bergere M, Bailly M, Boitrelle F, et al. Genetic polymorphisms influence the ovarian response to rFSH stimulation in patients undergoing in vitro fertilization programs with ICSI. PLoS One. 2012;7:e38700.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Morón FJ, de Castro F, Royo JL, Montoro L, Mira E, Sáez ME, et al. Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS). Pharmacogenet Genomics. 2006;16:485–95.CrossRefPubMed Morón FJ, de Castro F, Royo JL, Montoro L, Mira E, Sáez ME, et al. Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS). Pharmacogenet Genomics. 2006;16:485–95.CrossRefPubMed
20.
Zurück zum Zitat O’Brien TJ, Kalmin MM, Harralson AF, Clark AM, Gindoff I, Simmens SJ, et al. Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation. Reprod Biol Endocrinol. 2013;11:71.CrossRefPubMedPubMedCentral O’Brien TJ, Kalmin MM, Harralson AF, Clark AM, Gindoff I, Simmens SJ, et al. Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation. Reprod Biol Endocrinol. 2013;11:71.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Rizk B. Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online. 2009;19:14–27.CrossRefPubMed Rizk B. Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online. 2009;19:14–27.CrossRefPubMed
22.
Zurück zum Zitat Mattassi R, Manara E, Colombo PG, Manara S, Porcella A, Bruno G, et al. Variant discovery in patients with Mendelian vascular anomalies by next-generation sequencing and their use in patient clinical management. J Vasc Surg. 2018;67:922–932.e11.CrossRefPubMed Mattassi R, Manara E, Colombo PG, Manara S, Porcella A, Bruno G, et al. Variant discovery in patients with Mendelian vascular anomalies by next-generation sequencing and their use in patient clinical management. J Vasc Surg. 2018;67:922–932.e11.CrossRefPubMed
23.
Zurück zum Zitat Hsu C-C, Chiang C-W, Cheng H-C, Chang WT, Chou CY, Tsai HW, et al. Identifying LRRC16B as an oncofetal gene with transforming enhancing capability using a combined bioinformatics and experimental approach. Oncogene. 2011;30:654–67.CrossRefPubMed Hsu C-C, Chiang C-W, Cheng H-C, Chang WT, Chou CY, Tsai HW, et al. Identifying LRRC16B as an oncofetal gene with transforming enhancing capability using a combined bioinformatics and experimental approach. Oncogene. 2011;30:654–67.CrossRefPubMed
24.
Zurück zum Zitat Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008;14:321–33.CrossRefPubMed Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008;14:321–33.CrossRefPubMed
25.
Zurück zum Zitat Gómez R, Simón C, Remohí J, Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability1. Biol Reprod. 2003;68:2164–71.CrossRefPubMed Gómez R, Simón C, Remohí J, Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability1. Biol Reprod. 2003;68:2164–71.CrossRefPubMed
26.
Zurück zum Zitat Bahram F, Claesson-Welsh L. VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiol Off J Int Soc Pathophysiol. 2010;17:253–61. Bahram F, Claesson-Welsh L. VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiol Off J Int Soc Pathophysiol. 2010;17:253–61.
27.
Zurück zum Zitat Heinolainen K, Karaman S, D'Amico G, Tammela T, Sormunen R, Eklund L, et al. VEGFR3 modulates vascular permeability by controlling VEGF/VEGFR2 signaling. Circ Res. 2017;120:1414–25.CrossRefPubMed Heinolainen K, Karaman S, D'Amico G, Tammela T, Sormunen R, Eklund L, et al. VEGFR3 modulates vascular permeability by controlling VEGF/VEGFR2 signaling. Circ Res. 2017;120:1414–25.CrossRefPubMed
28.
Zurück zum Zitat Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7:199–205.CrossRefPubMed Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7:199–205.CrossRefPubMed
Metadaten
Titel
Rare genetic variants potentially involved in ovarian hyperstimulation syndrome
verfasst von
Katrien Stouffs
Sari Daelemans
Samuel Santos-Ribeiro
Sara Seneca
Alexander Gheldof
Ali Sami Gürbüz
Michel De Vos
Herman Tournaye
Christophe Blockeel
Publikationsdatum
27.11.2018
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 3/2019
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-018-1372-5

Weitere Artikel der Ausgabe 3/2019

Journal of Assisted Reproduction and Genetics 3/2019 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.